Add To Watchlist
Share URL
About The Company
CEO
Mr. Ron Bentsur M.B.A.
Market Cap
152.14 Million USD
Sector
Healthcare
Website
https://www.nuvectis.comDescription
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
Read More
Overview
Value
1
Growth
20
Health
29
Management
0
Analyst Opinion
60
Total
28
All Scores Out Of 100
Best Features
- Has a low level of debt
- Low preportion of income is paid as dividend 0
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Earnings are negative
- Poor overall financial health
- Poor earnings and cashflow growth
Latest News

These Are the 10 Best-Performing IPOs in 2022 Through October
24/7 Wall Street | 02:21 Thu 17 Nov 2022
Read More →

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
GlobeNewsWire | 22:30 Mon 3 Oct 2022
Read More →

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
GlobeNewsWire | 14:30 Wed 7 Sept 2022
Read More →

Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
GlobeNewsWire | 16:21 Fri 20 May 2022
Read More →
Market Peers
NVCT
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
N/A
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
N/A
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 8 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
0.14%
PE/Earnings Growth
N/A
Price/Book
5.74x
Growth
Growth Score
20
- ✔ Revenue growth has improved this yeara
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)
Revenue Growth
N/A
Earnings Growth
N/A
Cashflow Growth
N/A
Health
Health Score
29
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
N/Ax
Current Assets/Liabilities
2.41x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
N/Ax
Management
Management Score
0
Average Buybacks/Dilution
N/A
Recent Buybacks/Dilution
15.13%
5 Year Price Volitility
N/A
Return On Assets
-239913084.35%
Return On Capital Employed
-142022917.58%
Return On Equity
145085519.85%
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
60
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Nuvectis Pharma, Inc.
Currency
USD
Beta
0
Vol Avg
37622
Ceo
Mr. Ron Bentsur M.B.A.
Cik
0001875558
Cusip
67080T108
Exchange
NASDAQ Capital Market
Full Time Employees
8
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2022-02-04
Address
1 Bridge Plaza
City
Fort Lee
State
NJ
Country
US
Zip
07024
Phone
201 614 3150
All financial data provided by FMP